Evolus (EOLS) Stock Forecast & Price Target

Evolus Inc. reported a 3.7% year-over-year increase in total net revenue, reaching $69.4 million, propelled by a rise in Jeuveau sales and a successful launch of the Evolysse dermal filler line. The potential contribution from Evolysse to the top-line guidance is projected to be 10-12% for 2025, indicating strong market demand and growth driven by younger consumers who have a more favorable view of aesthetic treatments. Furthermore, the company's confidence in Jeuveau's ability to capture market share, coupled with a strategic focus on differentiated product offerings, positions Evolus for meaningful growth in the self-pay aesthetic market.

Evolus Inc. has experienced a decline in its adjusted gross margin, which fell to 66.5% from 71.5% year-over-year, primarily due to a higher proportion of international sales and introductory pricing strategies. The company has also revised its 2025 net revenue guidance downward to $295-$305 million, significantly lower than the previous estimate of $345-$355 million, indicating a slowdown in growth expectations from 30%-33% to merely 11%-15%. Additionally, Jeuveau's sales saw a notable drop of 13% quarter-over-quarter and 11% year-over-year in the second quarter of 2025, attributed to decreased consumer sentiment and overall softness in the U.S. aesthetic market.